Australian Clinical Labs Ltd. (ACL.AX) ACL FY26 Result: Cost control delivers earnings upgrade ACL.AX 12m Price Target: A$2.26 Price: A$2.70 Downside: 16.3% The key driver for ACL's FY26 earnings outperformance was largely driven by stronger cost control. The reduction in consumables cost (~80bps reduction as % of revenue 2H vs pcp) was a function of better pricing outcomes, with key suppliers noting the partial assistance by a change in test mix. This cost discipline appears set to continue in FY27 with AC ...